<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1367</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15018662</PubmedId>
            <Abstract>Insertion of a short-sized epitope at four different sites of yeast-expressed hamster polyomavirus major capsid protein VP1 has been found to result in the formation of chimeric virus-like particles. Here, we demonstrate that the insertion of 45 or 120 amino acid-long segments from the N-terminus of Puumala hantavirus nucleocapsid protein into sites 1 (amino acids 80-89) and 4 (amino acids 288-295) of VP1 allowed the highly efficient formation of virus-like particles. In contrast, expression level and assembly capacity of fusions to sites 2 (amino acids 222-225) and 3 (amino acids 243-247) were drastically reduced. Immunization of BALB/c mice with chimeric virus-like particles induced a high-titered antibody response against the hantavirus nucleocapsid protein, even in the absence of any adjuvant. The strongest response was observed in mice immunized with virus-like particles harboring 120 amino acids of hantavirus nucleocapsid protein. According to the immunoglobulin subclass distribution of nucleocapsid protein-specific antibodies a mixed Th1/Th2 response was detected. The VP1 carrier itself also induced a mixed Th1/Th2 response, which was found to be reduced in mice immunized with virus-like particles harboring 120 amino acid-long inserts. In conclusion, hamster polyomavirus VP1 represents a promising carrier moiety for future vaccine development.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>51-68</ArticlePages>
            <ArticleTitle>Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gedvilaite</LastName>
                    <ForeName>Alma</ForeName>
                </Author>
                <Author>
                    <LastName>Zvirbliene</LastName>
                    <ForeName>Aurelija</ForeName>
                </Author>
                <Author>
                    <LastName>Staniulis</LastName>
                    <ForeName>Juozas</ForeName>
                </Author>
                <Author>
                    <LastName>Sasnauskas</LastName>
                    <ForeName>Kestutis</ForeName>
                </Author>
                <Author>
                    <LastName>Kr√ºger</LastName>
                    <ForeName>Detlev H</ForeName>
                </Author>
                <Author>
                    <LastName>Ulrich</LastName>
                    <ForeName>Rainer</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Biotechnology, Vilnius, Lithuania.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Capsid Proteins;Nucleocapsid Proteins;Recombinant Fusion Proteins;VP1 protein, polyomavirus;Viral Vaccines;nucleocapsid protein, Puumala virus</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Viral(blood); Capsid Proteins(genetics; immunology; metabolism); Cricetinae; Immunization; Male; Mice; Mice, Inbred BALB C; Nucleocapsid(genetics; immunology); Nucleocapsid Proteins; Polyomavirus(genetics; immunology; metabolism); Puumala virus(genetics; immunology; metabolism); Recombinant Fusion Proteins(genetics; immunology; metabolism); Th1 Cells(immunology); Th2 Cells(immunology); Viral Vaccines(administration &amp; dosage; immunology); Virion(immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>17</Volume>
                <Issue>1</Issue>
                <Title>Viral immunology</Title>
                <Issn>0882-8245</Issn>
                <MedlineTa>Viral Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>VR45</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>45</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB01662.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>1980486</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Provided by author, Figures 2 and 4</LocationOfData>
                <EpitopeId>42533</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>45</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 4 and 5</LocationOfData>
                        <BCellId>21832</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>M</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ</LinearSequence>
                                            <StartingPosition>1</StartingPosition>
                                            <EndingPosition>45</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB01662.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1980486</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VR45-4</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 dose(s) of 50 ug antigen in PBS or emulsified in adjuvant</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Virus-like particles composed of self-assembled chimeric hamster polyomavirus major capsid protein (e.g., VP1/VR45-4; this means that the epitope (VR45) is inserted at position 4 (in place of amino acids 288-295) in VP1) were used as the immunogen. Schedule: one prime immunization with or without FCA; 2 booster immunizations with or without IFA on days 28 and 56 after the first immunization. Blood samples for detection of antibody titers and isotyping were collected at each injection and at days 34 and 70 after the final boost. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Immunoglobulins from mice immunized with hamster polyomavirus major capsid protein (VP1) containing the epitope (VR45) or an analog of the epitope (VR45M, contains a Y to D substitution at position 35) as an insert at position 4 (amino acid residues 288-295) react positively with full length Puumala virus nucleocapsid protein by ELISA. The nucleocapsid protein-specific IgG titers from immunizations with adjuvant are 10X higher than without. The IgG subclasses observed were IgG1, IgG2a, IgG2b and IgG3, indicating a mixed Th1/Th2 response.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Nucleocapsid protein</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAB01662.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1980486</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <BCellId>21828</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9986</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAB01662.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>1980486</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleocapsid protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Nucleocapsid protein-specific rabbit serum detects the epitope (VR45) or an analog of the epitope (VR45M, contains a Y to D substitution at position 35) inserted into either site 1 (amino acid residues 80-89) or site 4 (amino acid residues 288-295) of hamster polyomavirus major capsid protein (VP1). Similar results were observed by ELISA. .</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP1/VR45-1, VP1/VR45-4, VP1/VR45M-4</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB01662.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1980486</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2 and 3</LocationOfData>
                        <BCellId>21836</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Unknown</InVivoProcessType>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope for the monoclonal antibody A1C5 is located in the region that spans amino acids 14-39 of the source protein. This monoclonal antibody clearly detects the epitope within chimeric proteins with the peptide VR45 (covering amino acids 1-45 of the source protein) inserted into either site 1 (amino acid residues 80-89) or site 4 (amino acid residues 288-295) of hamster polyomavirus major capsid protein (VP1), or the peptide VR45M (an analog of VR45 containing a Y to D substitution at position 35) inserted into site 4 of VP1.  A1C5 detects VR45 inserted in position 1, but not in position 4 by ELISA.  The mAb also does not detect the analog, VR45M, inserted in position 4.  Another monoclonal antibody, 1C12, which has a similar but less defined epitope does not bind VR45 in either western blot or ELISA, but detects the analogue VR45M in both western blot and ELISA. .</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>A1C5</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>VP1/VR45-1, VP1/VR45-4, VP1/VR45M-4</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB01662.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>1980486</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 7</LocationOfData>
                        <TCellId>21834</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>M</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MSDLTDIQEDITRHEQQLVVARQKLKDAEKAVEMYPDDVNKNTLQ</LinearSequence>
                                            <StartingPosition>1</StartingPosition>
                                            <EndingPosition>45</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAB01662.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>1980486</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>VR45-4</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 dose(s) of 50 ug immunogen in PBS or emulsified in adjuvant</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Virus-like particles composed of self-assembled chimeric hamster polyomavirus major capsid protein (VP1/VR45-4; this means that the epitope (VR45) is inserted at position 4 (in place of amino acids 288-295) in VP1) were used as the immunogen. Schedule: one prime immunization with or without FCA; 2 booster immunizations with or without IFA on days 28 and 56 after the first immunization. Spleen cells for analysis were collected 34 days after the last immunization. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Nucleocapsid protein</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>AAB01662.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>1980486</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>73</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>2</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>2</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Upon stimulation, splenocytes from mice immunized with the epitope (VR45) or an analog of the epitope (VR45M, contains a Y to D substitution at position 35) inserted in position 4 (amino acid residues 288-295) of the hamster polyomavirus major capsid protein (VP1) produced cytokines IFNŒ≥ and IL-2 at levels above control (splenocytes from na√Øve mice). The use of adjuvant increased cytokine production.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

